Moderna's Price Target Adjustment and Challenges
Recently, prominent analysts at Jefferies have downgraded their outlook on Moderna (NASDAQ: MRNA), reducing the price target to $55 from the previous $65. This adjustment is driven by several underlying factors, including lower-than-expected guidance for upcoming years and delays in the much-anticipated cost reductions. Their second-quarter earnings report raised concerns as forecasts for 2024 were notably reduced, coupled with subsequent announcements during the R&D day that left expectations for 2025 diminished.
Competitive Landscape and Financial Woes
One significant cause of concern is the anticipated performance of Moderna's Respiratory Syncytial Virus (RSV) vaccine. Current projections for 2024 are modest at best, and there remains a cloud of uncertainty surrounding the company's ability to procure contracts in 2025. Still, competitive pressures from pharmaceutical giants, namely GSK and Pfizer (NYSE: PFE), exacerbate this complexity, especially with the ambiguity surrounding vaccine recommendations for the forthcoming RSV season. Analysts have also flagged Moderna's high cash burn rate, which remains elevated at $5-6 billion. As a result, profitability forecasts have been pushed back to 2028, changing from earlier expectations set for 2026.
Looking Ahead: Potential for Growth
Despite these hurdles, some optimism lingers. Analysts suggest that positive interim results from the Cytomegalovirus (CMV) vaccine could provide a much-needed boost to the stock in the near future. When discussing the financial outlook for the third quarter, Moderna projects revenues between $2.6-3.2 billion for the remainder of the year. They expect approximately 40% of COVID-19 revenues to be recorded in the third quarter, with predictions of about $1-1.2 billion for that specific quarter.
Revenue Estimates and Projections
The latest forecasts estimate around $1 billion in revenue, with an anticipated $540 million coming from U.S. sales. These estimates rely on 4 million tracked retail prescriptions and an anticipated 30% share from non-retail channels at a net price of $80 per shot. The company's guidance for the second half shows a projected split of about $670 million each from the Advanced Purchase Agreement (APA) and ex-U.S. COVID-19 sales. This scenario implies roughly $270 million for each segment during the third quarter, culminating in approximately $540 million in total—substantially lower than the consensus estimate of around $1.2 billion.
Leadership Changes and Clinical Trials
In a move towards enhancing its strategic positioning, Moderna has recently appointed Abbas Hussain, the previous CEO of Vifor Pharma and Global President of GlaxoSmithKline's Pharmaceuticals and Vaccines, to its board of directors. His extensive industry experience is expected to be instrumental in guiding Moderna's commercialization efforts on a global scale.
New Vaccine Trials and Product Launches
Further advancing its portfolio, Moderna has initiated a pivotal Phase 3 clinical trial for its investigational norovirus vaccine, mRNA-1403, aiming to enroll roughly 25,000 participants across the globe. Additionally, the company has received approval from Health Canada for its updated COVID-19 vaccine, SPIKEVAX®, which is set to be deployed for the 2024-2025 season.
Market Outlook and Analyst Reactions
Recent adjustments by various analyst firms signify a cautious outlook for Moderna. For instance, Piper Sandler has lowered its target for the company from $157 to $115 while maintaining an Overweight rating. Meanwhile, Oppenheimer has relegated the company's stocks to a neutral status, indicating a Perform rating. Similarly, RBC Capital has adjusted its price target from $90 to $75, reflecting growing skepticism about Moderna's future profitability and revenue generation capabilities.
Overall, Moderna estimates its product sales to be between $3 billion and $3.5 billion for the current year, looking to navigate through challenging financial waters. However, the timeline for reaching cash flow breakeven has been deferred to 2028, which includes projected revenue around $6.0 billion—an essential consideration for investors monitoring the company's trajectory.
Frequently Asked Questions
What led Jefferies to cut Moderna's price target?
Jefferies cut Moderna's price target due to lower-than-expected guidance, competition, and delays in cost reductions.
How does Moderna plan to improve its revenue?
Moderna anticipates significant revenue from COVID-19 sales, and potential growth from its upcoming CMV vaccine data.
What are the financial challenges facing Moderna?
Moderna faces high cash burn rates and delayed profitability forecasts, now pushed to 2028.
Who has been appointed to Moderna's board recently?
Abbas Hussain, former CEO of Vifor Pharma, has been appointed to Moderna's board to enhance commercialization efforts.
What is the status of Moderna's RSV vaccine?
Projections for Moderna's RSV vaccine are currently minimal for 2024, raising concerns about future contracts.
